BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
0.711
+0.044 (6.57%)
At close: Oct 29, 2024, 4:00 PM
0.720
+0.009 (1.29%)
After-hours: Oct 29, 2024, 7:42 PM EDT

BioXcel Therapeutics Stock Forecast

BTAI's stock price has decreased by -76.54% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 4 analysts with 12-month price forecasts for BTAI stock have an average target of 5.00, with a low estimate of 1.00 and a high estimate of 7.00. The average target predicts an increase of 603.43% from the current stock price of 0.71.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $1.00 $5.00 $7.00 $7.00
Change +40.69% +603.43% +884.81% +884.81%

Analyst Ratings

The average analyst rating for BTAI stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating May '24Jun '24Jul '24Aug '24Sep '24Oct '24
Strong Buy 333333
Buy 000000
Hold 555221
Sell 000000
Strong Sell 000000
Total 888554

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$7$5
Strong Buy Maintains $7$5 +603.43% Oct 21, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$7
Strong Buy Reiterates $7 +884.81% Sep 6, 2024
Canaccord Genuity
Canaccord Genuity
Strong Buy
Maintains
$7
Strong Buy Maintains $7 +884.81% Aug 30, 2024
UBS
UBS
Hold
Maintains
$3.5$1
Hold Maintains $3.5$1 +40.69% Aug 9, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$10$7
Strong Buy Maintains $10$7 +884.81% Aug 8, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
4.88M
from 1.38M
Increased by 253.55%
Revenue Next Year
9.99M
from 4.88M
Increased by 104.78%
EPS This Year
-2.01
from -6.15
EPS Next Year
-1.78
from -2.01
Fiscal Year FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026
Period Ending Dec 31, 2019 Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026
Revenue
---375.00K1.38M4.88M9.99M24.22M
Revenue Growth
----268.00%253.55%104.78%142.40%
EPS
-2.02-3.79-4.05-5.92-6.15-2.01-1.78-1.54
EPS Growth
--------
Forward PE
--------
No. Analysts -----886
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20242025202620272028
High 5.6M 11.4M 26.3M
Avg 4.9M 10.0M 24.2M
Low 4.2M 8.6M 22.4M

Revenue Growth

Revenue Growth 20242025202620272028
High
308.6%
133.9%
162.7%
Avg
253.6%
104.8%
142.4%
Low
203.9%
77.0%
124.6%

EPS Forecast

EPS 20242025202620272028
High -1.75 -1.09 -0.90
Avg -2.01 -1.78 -1.54
Low -2.33 -2.68 -2.50

EPS Growth

EPS Growth 20242025202620272028
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.